InMode, Daktronics, Domino’s Pizza And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session.
Benzinga’s Top Ratings Upgrades, Downgrades For June 21, 2023
Upgrades Goldman Sachs upgraded the previous rating for Petroleo Brasileiro SA Petrobras (NYSE:PBR) from Neutral to Buy. Petrobras…
Benzinga’s Top Ratings Upgrades, Downgrades For June 12, 2023
Upgrades For adidas AG (OTC:ADDYY), Bernstein upgraded the previous rating of Market Perform to Outperform. In the first…
Benzinga’s Top Ratings Upgrades, Downgrades For March 17, 2023
Upgrades Redburn Partners upgraded the previous rating for FMC Corp (NYSE:FMC) from Neutral to Buy. For the fourth…
Centessa Pharmaceuticals To Present Additional Data From Open-Label Extension Of Phase 2a Study Of SerpinPC For Hemophilia At The 16th Annual Congress Of The European Association For Haemophilia And Allied Disorders On February 10, 2023
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present
Centessa Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.57) per share. This is a 26.67 percent decrease over losses of $(0.45) per share from the same period last year.
Centessa Pharmaceuticals Announces Poster Presentation At 26th Conference of the European Sleep Research Society
BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been
Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
FDA Grants Orphan Drug Status To Centessa’s Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B.
A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.
Morgan Stanley Downgrades Centessa Pharmaceuticals to Underweight, Lowers Price Target to $5
Morgan Stanley analyst Matthew Harrison downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Overweight to Underweight and lowers the price target from $10 to $5.